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Objectives. The present study examined left ventricular (LV) 
and myocyte contractile performance and electrophysiologic vari- 
ables after long-term digoxin treatment in a model of LV failure. 
Background. A fundamental therapeutic agent for patients with 
chronic LV dysfunction is the cardiac glycoside digoxin. However, 
whether digoxin has direct effects on myocyte contractile function 
and electrophysioiogic properties in the setting of chronic LV 
dysfunction remains unexplored. 
Methods. Left ventricular and isolated myocyte function and 
electrophysiologic variables were examined in five control dogs, 
five dogs after the development of long-term rapid pacing (rapid 
pacing, 220 beats/min, 4 weeks) and five dogs with rapid pacing 
given digoxin (0.25 mg/day) during the pacing period (rapid 
pacing and digoxin). 
Results. Left ventricular ejection fraction decreased in the dogs 
with rapid pacing compared with that in control dogs (30 ,+ 2% vs. 
68 + 3%, p < 0.05) and was higher with digoxin than that in the 
rapid pacing group (38 -+ 3%, p = 0.038). Left ventricular 
end-diastolic volume increased in the rapid pacing group com- 
pared with the control group (84 ,+ 6 ml vs. 59 -+ 7 ml, p < 0.05) 
and remained increased with digoxin (79 + 6 ml). Isolated 
myocyte shortening velocity decreased in the rapid pacing group 
compared with the control group (37 ,+ 1 pm/s vs. 59 -+ 1/tm/s, 
p < 0.05) and increased with digoxin compared with rapid pacing 
(46 ,+ 1 pm/s, p < 0.05). Action potential maximal upstroke 
velocity was diminished in the rapid pacing roup compared with 
the control group (135 .+ 6 V/s vs. 163 ,+ 9 V/s, p < 0.05) and 
increased with digoxin compared with rapid pacing (155 -+ 12 V/s, 
p < 0.05). Action potential duration increased inthe rapid pacing 
group compared with the control group (247 _+ 10 vs. 216 ,+ 6 ms, 
p < 0.05) and decreased with digoxin compared with rapid pacing 
(219 ,+ 12 ms, p < 0.05). 
Conclusions. In this model of rapid pacing.induced LV failure, 
digoxin treatment improved LV pump function, enhanced isolated 
myocyte contractile performance and normalized myocyte action 
potential characteristics. This study provides unique evidence to 
suggest that the cellular basis for improved LV pump function 
with digoxin treatment in the setting of LV failure has a direct and 
beneficial effect on myocyte contractile function and electrophysi- 
ologic measures. 
(J Am Coil Cardiol 1996;28:495-505) 
Cardiac glycosides uch as digoxin have been used in the 
treatment ofcardiac diseases for over 200 years (1-3). Today, 
digoxin is routinely administered to patients with congestive 
heart failure. Several recent clinical trials have demonstrated 
that chronic digoxin administration in congestive heart failure 
improves left ventricular (LV) function and reduces the sever- 
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ity of subjective symptoms (4-7). In addition, short-term 
administration f digoxin in the setting of severe heart failure 
produces favorable hemodynamic changes (8,9). Proposed 
mechanisms for the beneficial effects of digoxin treatment in
the setting of congestive heart failure include inotropic effects, 
alterations in systemic neurohormonal activation, modulation 
of baroreceptor reflexes and effects on conduction and heart 
rate (10). Although one or all of these ffects may be operative 
with respect o digoxin in the setting of heart failure, the 
fundamental nd specific effects on LV and myocyte function 
with long-term digoxin treatment during the progression of LV 
pump failure remain unknown (11). Accordingly, the overall 
objective of the present study was to determine the direct 
effects of long-term digoxin therapy on LV and myocyte 
contractile performance during the development of chronic 
LV dysfunction. 
Our laboratory, as well as those of others, has demonstrated 
that long-term pacing-induced tachycardia n animals causes 
LV dilation and dysfunction (12-15). This model of long-term 
rapid pacing causes increased neurohormonal ctivity and 
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signs and symptoms consistent with the clinical spectrum of 
congestive heart failure (14,16,17). These characteristics have 
resulted in the recognition of this model as an important new 
avenue in basic research on LV pump failure (18). In addition 
to changes in LV pump function and neurohormonal ctivity, 
it has also been demonstrated that fundamental defects in 
isolated myocyte contractile performance occur in this model 
of LV failure (15). Long-term digoxin treatment modulates 
heart rate through direct cellular effects, through modifications 
of autonomic neural input and through changes in myocardial 
sympathetic sensitivity (19), and this rate-slowing effect, in and 
of itself, may provide a beneficial effect in congestive heart 
failure, independent of the potential effects digoxin may have 
on LV and myocyte function. Because the model of 
tachycardia-induced LV dysfunction isachieved through main- 
taining a chronically elevated heart rate, the confounding 
influence of heart rate modulation, which may occur in long- 
term digoxin therapy, is eliminated. Therefore, this model 
provides a means to determine the direct effects of digoxin 
treatment on LV and myocyte function in the setting of chronic 
LV failure. Accordingly, the present study utilized this model 
to test the central hypothesis that long-term digoxin treatment 
has direct and beneficial effects on LV and myocyte function 
with the development of LV failure. 
Methods  
The present study used a model of rapid ventricular pacing 
in chronically instrumented dogs that has been well described 
previously (20). A subset of dogs was treated with digoxin 
during the rapid pacing protocol. In light of the fact that 
digoxin is clinically given with a diuretic, furosemide was 
administered daily to the dogs in the rapid pacing group, with 
or without concomitant digoxin treatment. To assess the 
potential effects of digoxin in normal myocardium, a subset of 
control dogs was also given digoxin. After a 4-week pacing 
protocol, LV hemodynamic measures were studied, hearts 
were harvested and myocytes were isolated for contractile 
function and electrophysiologic studies. 
Model of pacing-induced LV pump failure. Eighteen adult 
mongrel dogs of either gender (9 to 16 months of age, 15 to 
25 kg, provided by Hazelton) were used in this study. The 
animals were chronically instrumented to measure LV and 
arterial pressures. In addition, a pacemaker and stimulating 
electrode were implanted to produce rapid right ventricular 
pacing. Briefly, the animals were anesthetized with thiopental 
(2 mg/kg body weight Pentothal, Abbot Labs), intubated and 
ventilated with oxygen. Maintaining a surgical plane of anes- 
thesia with 1% to 3% isoflurane (Aurthan, Anaquest), a left 
thoracotomy was performed, and a shielded stimulating elec- 
trode was sutured onto the right ventricular outflow tract and 
connected to a programmable pacemaker previously modified 
for pacing rates up to 300 beats/min (Speetrax 5985, 
Medtronic, Inc.). A previously calibrated microtip transducer 
(model p5-X4, Konigsberg Instruments) was placed into the 
left ventricle through a small incision at the apex. The right 
carotid artery was exposed and a vascular access port (model 
GPV, 9F, Access Technologies) was placed in the artery, 
advanced to the aortic arch and sutured in place for subse- 
quent arterial blood pressure monitoring. The animals were 
allowed a 14-day recovery period, after which proper operation 
of all implanted instrumentation was confirmed. All animals 
used in this study were treated and cared for in accordance 
with the National Institutes of Health's (NIH) Guide for the 
Care and Use of Laboratory Animals (National Research 
Council 1985, NIH publication o. 86-23). 
Experimental design. After recovery from the surgical 
procedure just described, baseline LV pressure and dimen- 
sions and arterial pressure were measured. The pacemakers 
were then activated for rapid ventricular pacing (216 + 2 
beats/min), and 1:1 capture was confirmed by electrocardiog- 
raphy. The dogs were then randomly assigned to one of four 
protocols: 1) Rapid pacing and digoxin: Five dogs were given 
oral digoxin (0.25 mg/day) with a maintenance dose of oral 
furosemide (20 mg twice a day) during the 4-week pacing 
period. 2) Rapid pacing only: Five dogs were given gelatin 
capsule placebos and a maintenance dose of oral furosemide 
(20 mg twice a day) during the pacing period. 3) Sham control: 
Five dogs were instrumented and cared for in an identical 
manner to the groups just described, with the exception of 
activation of the pacemaker and drug treatment. 4) Drug 
control: Three instrumented ogs were given oral digoxin 
(0.25 mg/day) without rapid ventricular pacing or the addi- 
tional administration of furosemide. The digoxin dose was 
based on previously published work in the species (21). Car- 
diac auscultation and an electrocardiogram (ECG) were per- 
formed frequently during the 28-day pacing protocol to ensure 
proper pacemaker function and the presence of 1:1 capture. 
Left ventricular function and plasma norepinephrine mea- 
surements. Indexes of LV systolic and diastolic function were 
obtained at baseline and after the 28-day pacing period using 
simultaneously recorded pressure and echocardiographic mea- 
surements previously described (22-24). All measurements 
were performed at least 30 min after pacemaker deactivation, 
in a darkened room, with the animal resting quietly in a sling. 
Pressures from the fluid-filled aortic catheter were obtained 
using an externally calibrated transducer (Statham P23ID, 
Gould). The ECG and pressure waveforms were recorded 
using a multichannel recorder (Gould, TA4000) and digitized 
for subsequent analysis (PO-NE-MAH). Two-dimensional nd 
M-mode echocardiographic studies (ATL Ultramark 7, 3.5- 
MHz transducer) were used to image the left ventricle from a 
right parasternal pproach. Left ventricular volumes, cardiac 
output and ejection fractions were computed from the two- 
dimensional and M-mode echocardiographic recordings 
(23,24). The peak rates of positive and negative left ventricular 
pressure change (dP/dt), peak systolic wall stress and end- 
systolic wall stress were computed using methods described 
previously (24). Finally, LV mass was computed from the 
two-dimensional targeted echocardiographic recordings using 
previously validated methods (23). 
To examine the relation between changes in plasma nor- 
JACC Vol. 28, No. 2 McMAHON ET AL. 497 
August 1996:495-505 DIGOXIN IN LV DYSFUNCTION 
epinephrine levels, which may accompany changes in LV 
function with long-term rapid pacing with or without concom- 
itant digoxin therapy, blood samples were drawn at the end of 
the study. With the animal resting quietly, 5 ml of blood was 
drawn from the arterial access port into tubes containing 
ethylenediaminetetraacetic id (1.5 mg/ml), sodium azide (0.2 
mg/ml) and aprotinin (1.15 trypsin inhibition units/ml). The 
blood samples were immediately centrifuged (2,000g, 10 min, 
4°C), and the plasma was decanted into separate tubes, frozen 
in a dry ice/methanol bath and stored at -80°C until the time 
of assay. From these plasma samples, norepinephrine concen- 
tration was determined in duplicate using high performance 
liquid chromatography and normalized to pg/ml of plasma 
(25). In the dogs randomized to chronic digoxin therapy, 
plasma was also obtained for trough digoxin levels. Plasma 
digoxin levels were measured using a commercially available 
fluorescence polarization immunoassay (TDxFLx System, Ab- 
bott Laboratories). 
Myocyte isolation and contractile function measurements. 
Myocytes were isolated from the LV free wall using methods 
described by our laboratory previously (15,17,26,27). Briefly, 
the region of the LV free wall incorporating the left circumflex 
coronary artery was perfused with a collagenase solution (0.5 
mg/ml, Worthington, type II; 146 U/mg) for 35 min. The tissue 
was then minced into 2-ram sections and gently agitated. After 
15 min, the supernatant was removed and filtered and the cells 
were allowed to settle. Using this myocyte isolation method, a
high yield of viable myocytes was routinely obtained for 
myocyte contractile function and electrophysiologic measure- 
ments as described in the following sections. 
Isolated myocytes were placed in a thermostatically con- 
trolled chamber (37°C) fitted with a coverslip on the bottom 
for imaging on an inverted microscope (Sedival, Jena, Germa- 
ny). Isolated myocytes were imaged using a 20x long working- 
distance objective. Myoc3,te contractions were elicited by field 
stimulation at 1 Hz (Sll, Grass Instruments) and imaged using 
a charge-coupled device with a noninterlaced scan rate of 
240 Hz (GPCD60, Panasonic). Myocyte motion signals were 
captured with the cell parallel to the video raster lines, and this 
video signal was input through an edge detector system 
(Crescent Electronics). The distance between the left and right 
myocyte dges was converted into a voltage signal, digitized 
and input to a computer (80486, Zeos International) for 
subsequent analysis. Stimulated myocytes were allowed a 
5-rain stabilization period, after which contraction data for 
each myocyte were recorded from a minimum of 20 consecu- 
tive contractions. Variables computed from the digitized con- 
traction profiles included percent shortening (%), peak veloc- 
ity of shortening (~m/s) and peak velocity of relengthening 
(/zm/s). After collection of baseline indices of myocyte func- 
tion, measurements were then repeated in the presence of 25 
nmolfliter of ( - )  isoproterenol (17). 
Myocyte action potential measurements. Myocytes were 
impaled by gently advancing microelectrodes (tip resistances 
20 to 35 M[I) onto the sarcolemmal surface using a microma- 
nipulator (MO-103; Narshige Instruments, Tokyo, Japan). 
Myocyte action potentials were elicited by current injection 
through the microelectrode using 1-ms pulses at intervals of 
1,000 ms. Impalements were considered stable if myocytes 
could be stimulated continuously for 10 rain with stable rest 
membrane potential, action potential duration and contraction 
amplitude (28). Myocyte action potential signals were col- 
lected from a minimum of five consecutive contractions, 
digitized at 12-bit resolution at a sampling frequency of 10 kHz 
(AT-MIO-16; National Instruments) and stored on computer 
disk (80486, Zeos International). Action potential variables 
derived from the undifferentiated and differentiated mem- 
brane potential signals included rest membrane potential 
(mV), action potential amplitude (mV), action potential dura- 
tions at 50% (APD50) and 90% (APD9o) repolarization (ms) 
and the maximal action potential upstroke velocity (V/s). 
Action potential amplitude was computed as the difference 
between the peak membrane potential and the rest membrane 
potential. The APD50 and APD90 were computed as the time 
required for the action potential to repolarize to 50% and 10% 
of the action potential amplitude, respectively. Maximal action 
potential upstroke velocity was defined as the peak value of the 
differentiated membrane potential signal. 
Myocyte cross-sectional rea measurements. The left an- 
terior descending coronary artery specimen of LV myocardium 
previously isolated for microscopic analysis was perfused with 
a buffered sodium cacodylate solution containing 2% para- 
formaldehyde and 2% glutaraldehyde (pH 7.4, 325 mOsm) for 
20 min using a perfusion pressure of 100 mm Hg (15). Light 
microscopic examination at a magnification of 1,000× was 
performed on the perfusion-fixed LV myocardium to deter- 
mine myocyte cross-sectional rea. Myocytes in a cross- 
sectional orientation were digitized and analyzed using an 
image analysis ystem (IBAS, Kontron, Germany). Only those 
myocytes inwhich the nucleus was centrally located within the 
cell were digitized and analyzed to ensure that the short axis of 
the myocyte was perpendicular to the microscope objective. 
Using this approach, myocyte cross-sectional rea could be 
determined in situ. 
Data analysis. Indexes of LV and myocyte function were 
compared among the treatment groups using analysis of vari- 
ance (ANOVA). Analysis of the morphologic data was per- 
formed using the average measurements obtained for each 
animal, and the groups were compared using ANOVA. For the 
myocyte function and electrophysiologic studies, ANOVA 
using a randomized block, split-plot design was employed. The 
treatment effects were pacing and digoxin therapy. Each dog 
was considered a complete block. Thus, the number of myo- 
cytes studied from each dog were considered repeated obser- 
vations within each block. The summary statistics include the 
number of myocytes studied from each group; however, all 
statistical comparisons were performed on a per dog (block) 
basis. If ANOVA revealed significant differences, pairwise 
tests of individual group means were compared using Bonfer- 
roni probabilities (29). For comparisons ofplasma norepineph- 
rine and digoxin levels between groups, the Mann-Whitney 
rank-sum test was employed (29). All statistical procedures 
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Table 1. Changes in Left Ventricular Function With Chronic Rapid 
Pacing: Effects of Long-Term Digoxin Treatment 
Rapid 
Rapid Pacing + 
Control Pacing Digoxin 
Group Group Group 
(n 5) (n- 5) (n : 5) 
Rest heart rate (beats/min) 79 ± 4 125 ± 8* 93 ± 12 
Mean arterial pressure 108.4 ± 4.3 98.5 ± 2.5 98.3 ± 1.8 
(ram Hg) 
LV systolic pressure 126.5 +_ 4.9 112.2 _+ 3.9* 115.2 ± 2.6 
(mm Hg) 
LV end-diastolic pressure 9.3 _+ 1.5 16.9 ± 1.0' 11.8 + 0.7i" 
(mm Hg) 
LV peak +dP/dt 2,465 ± 152 1,702 ± 100" 1,916 ± 112' 
(mm Hg/s) 
LV end-diastolic volume 58.9 ± 6.6 84.4 ± 6.2* 78.6 ± 6.1" 
(ml) 
LV ejection fraction (%) 68.3 ± 3.3 30.4 ± 1.6" 37.5 ± 2.8"t 
LV peak wall stress (g/cm 2) 125 ± 9 219 _+ 15' 191 +_ 17' 
LV end-systolic wall stress 111 _+ 10 173 _+ 6* 164 _+ 5* 
(g/cm ~) 
Cardiac output (liters/rain) 4.3 + 0.7 2.6 ± 0.2* 3.0 _+ 0.3 
LV mass/body weight 6.1 ± 0.3 6.0 ± 0.6 5.4 ± 0.3 
(g~g) 
*p < 0.05 versus control group, tP < 0.05 versus rapid pacing group. Data 
presented are mean values +_ SEM. dP/dt = peak rate of change in left 
ventricular (LV) pressure; Rapid Pacing = 28 days of right ventricular pacing at 
210 beats/rain; Rapid Pacing + Digoxin = rapid pacing with concomitant digoxin 
(0.25 mg/day). 
were performed using the BMDP statistical software package 
(BMDP Statistical Software Inc.). Results are presented as 
mean _+ SEM. Values of p < 0.05 were considered to be 
statistically significant. 
Results 
Hemodynamic, echocardiographic and ECG studies were 
successfully performed in all experimental animals in the 
present study. In all of the dogs used in this study, the 
prepacing basal value for LV ejection fraction was 62 _+ 3% 
and the LV end-diastolic volume was 53 _+ 4 ml. Hearts were 
harvested and myocytes were successfully isolated from all 
animals at the end of the study, with no significant difference in 
the yield of viable myocytes obtained (76 ___ 3%). In those dogs 
that underwent long-term digoxin therapy, plasma digoxin 
levels were 1.2 _+ 0.2 ng/ml (range 0.6 to 3.1). 
Left ventrieular function and electrocardiography: effect of 
rapid pacing and concomitant digoxin therapy. Indexes of LV 
function in control, chronic rapid pacing and chronic rapid 
pacing with concomitant digoxin treatment groups are shown 
in Table 1. In the present study, chronic rapid pacing with the 
addition of daily furosemide treatment caused significant LV 
dilation and dysfunction. The values obtained are identical to 
those obtained in dogs after chronic rapid ventricular pacing 
without furosemide treatment (30). Therefore, the present 
study demonstrated that concomitant diuretic therapy during 
chronic rapid pacing failed to prevent LV dilation and dysfunc- 
tion. In the group of dogs treated with digoxin during chronic 
rapid pacing compared with the chronic rapid pacing only 
group, there was a small but significant increase in LV ejection 
fraction (p = 0.038). Left ventricular end-diastolic volume was 
slightly lower in the pacing group treated with digoxin com- 
pared with rapid pacing only group, but the difference did not 
reach statistical significance (p = 0.52). Left ventricular systolic 
pressure was significantly lower in the rapid pacing-only group 
compared with the control group. Left ventricular systolic 
pressure was lower in the pacing group treated with digoxin 
than in the control group, but this difference failed to reach 
statistical significance (p = 0.078). Compared with the control 
group, LV mass was unchanged inthe chronic rapid pacing and 
chronic rapid pacing with concomitant digoxin administration 
groups. To investigate the relation between changes in LV 
pressure and geometry with chronic rapid pacing and with 
concomitant digoxin treatment, LV peak systolic and LV 
end-systolic wall stresses were computed. Chronic rapid pacing 
caused a significant increase in both LV peak and LV end- 
systolic wall stress. Both LV peak and end-systolic wall stresses 
were lower in the rapid pacing group treated with digoxin 
compared with the rapid pacing only group, but these differ- 
ences failed to reach statistical significance (p = 0.16 and p = 
0.39, respectively). Thus, concomitant digoxin administration 
with chronic rapid pacing improved LV pump function but did 
not prevent he alterations in LV geometry, which occurred 
with chronic rapid pacing. 
In control dogs that underwent long-term digoxin adminis- 
tration, there was no change in LV geometry or function 
compared with untreated normal dogs. Specifically, there was 
no change in LV end-diastolic volume (73 _+ 22 ml, p = 0.5) or 
in LV ejection fraction (66 _+ 3%, p = 0.6) in control dogs 
treated with digoxin compared with untreated normal dogs. 
Similarly, there was no change in peak LV wall stress (147 ___ 
6 g/cm 2, p = 0.14), mean arterial pressure (114.6 _+ 7.9 mm Hg, 
p = 0.48) or the LV mass to body weight ratio (5.6 _+ 0.9, p = 
0.6) in control dogs treated with digoxin compared with 
untreated normal dogs. Thus, long-term digoxin therapy in the 
presence of normal myocardium had no effect on LV geometry 
and function. 
In the chronic rapid pacing group, the plasma norepineph- 
rine concentration was 404 +_ 63 pg/ml, which was significantly 
elevated compared with the control group (146 _+ 16 pg/ml, 
p < 0.05). With digoxin treatment, he plasma norepinephrine 
concentration was decreased from rapid pacing alone (245 _+ 
30 pg/ml, p < 0.05), but remained greater than that in the 
control group (p < 0.05). Thus, concomitant digoxin treatment 
modulated the increase in systemic norepinephrine l vels 
which occurred with chronic rapid pacing. 
Electrocardiographic variables measured at the end of the 
study are shown in Table 2. All ECGs were recorded at an 
ambient rest heart rate at least 30 rain after pacemaker 
deactivation (paced dogs only). The RR interval, which was 
computed as a measure of the rest heart rate, was increased in 
the chronic rapid pacing with concomitant digoxin treatment 
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Table 2. Changes in Electrocardiographic Variables With Chronic 
Rapid Pacing: Effects of Long-Term Digoxin Treatment 
Rapid Pacing + 
Control Group Rapid Pacing Group Digoxin Group 
(n=5)  (n=5)  (n=5)  
RR interval (ms) 701 _+ 34 524 ± 29* 756 -+ 87t 
PR interval (ms) 111 _+ 3 126 ± 3* 157 _+ 4*t 
QRS duration (ms) 63 ± 2 72 ± 3* 71 _+ 1" 
QTc interval (ms) 292 ± 4 331 +_ 6* 269 : 9t 
*p < 0.05 versus control group, tp < 0.05 versus rapid pacing group. Data 
presented are mean value ± SEM. QTc = corrected QT interval for heart rate 
using Bazett's formula; Rapid Pacing = 28 days of right ventricular pacing at 210 
beats/rain; Rapid Pacing + Digoxin = rapid pacing with concomitant digoxin 
(0.25 mg/day). 
group compared with the chronic rapid pacing only group. The 
PR interval was significantly increased in the chronic rapid 
pacing with concomitant digoxin therapy group compared with 
the control and rapid pacing only groups. QRS duration was 
prolonged in both the chronic rapid pacing and the chronic 
pacing with digoxin treatment groups compared with that in 
the control group. The corrected QT interval (QTc), which was 
prolonged by chronic rapid pacing, was decreased in the rapid 
pacing with digoxin group compared with the rapid pacing only 
group. Thus, the chronic rapid pacing and chronic rapid pacing 
with concomitant digoxin treatment groups displayed ifferen- 
tial effects with respect to ECG variables when compared with 
the control group. 
Isolated myocyte geometry and contractile function: effect 
of rapid pacing and concomitant digoxin therapy. A summary 
of isolated myocyte rest length and contractile function is 
shown in Table 3. Isolated myocyte rest length increased 
compared with control values after 4 weeks of rapid pacing in 
both groups of paced dogs, but was significantly lower in the 
pacing group with concomitant digoxin treatment. To more 
carefully examine the structural basis for the changes in LV 
and myocyte geometry in the rapid pacing groups, perfusion- 
fixed myocardial sections were examined using light micros- 
copy. Myocyte cross-sectional rea was significantly lower in 
the rapid pacing only group compared with the control group 
(272 _+ 4/xm 2 vs. 318 - 4/zm 2, respectively, p < 0.001). Rapid 
pacing with concomitant digoxin treatment caused an increase 
in myocyte cross-sectional rea over the rapid pacing only 
values (302 _ 4 p~m 2, p < 0.001). However, this value remained 
significantly lower than the control group value (p = 0.01). 
Representative contraction profiles of isolated myocytes 
taken from animals in the control, rapid pacing and rapid 
pacing with concomitant digoxin groups are shown in Figure 1. 
Compared with the control group, isolated myocyte percentage 
and velocity of shortening were significantly reduced with 
chronic rapid pacing and with chronic rapid pacing with 
concomitant digoxin treatment. However, compared with the 
rapid pacing only group, percent shortening and velocity of 
shortening were each 24% greater in the rapid pacing with 
concomitant digoxin administration group. Similarly, velocity 
of relengthening was diminished in both pacing groups corn- 
Table 3. Isolated Myocyte Contractile Performance With Chronic 
Rapid Pacing: Effects of Long-Term Digoxin Treatment 
Isoproterenol Calcium 
Baseline (25 nmol/liter) (8 mmol/liter) 
Rest length (~m) 
Control 
Control + digoxin 
Rapid pacing 
Rapid pacing + digoxin 
Percent shortening (%) 
Control 
Control + digoxin 
Rapid pacing 
Rapid pacing + digoxin 
Shortening velocity (/zm/s) 
Control 
Control + digoxin 
Rapid pacing 
Rapid pacing + digoxin 
Relengthening velocity (/zm/s) 
Control 
Control + digoxin 
Rapid pacing 
Rapid pacing + digoxin 
No. of cells 
Control 
Control + digoxin 
Rapid pacing 
Rapid pacing + digoxin 
152 ± 1 148 ± 15 147 ± 4 
154 ± 1 147 ± 2:) 145 ± 3 
172 ± 1" 163 ± 1":) 169 ± 5* 
162 ± l*t 153 ± 1"~ 153 ± 2t:) 
4.2 ± 0.1 10.3 + 0.2:) 10.4 ± 0.8:) 
4.2 ± 0.1 10.2 ± 0.2~: 9.8 ± 0.7:) 
2.5 ± 0.1" 7.2 + 0.2*:) 6.9 -+ 0.7*:) 
3.1 + 0.1*t 9.5 ± 0.2"~: 6.3 ± 0.5*:) 
59.3 ~ 1.0 187.9 ± 5.8~ 160.9 ± 18.2~ 
56.6 = 1.5 189.9 ±6.9:) 154.4 ± 15.1~ 
36.8 ± 1.0" 132.0 ±4.2'~ 111.1 ± 13.4"~ 
45.7 ± 0.9"t 170.7 ± 5.6'~ 101.1 ± 10.7"~ 
60.5 ± 1.2 197.5 ± 5.9~ 186.8 ±20.6~ 
57.9 + 1.9 187.1 ~ 7.4~ 157.4 ± 14.1:) 
32.5 ± 1.0' 124.3 + 4.4"~ 111.8 ± 13.6'~ 
45.2 + 1.1*t 168.9 ~ 6.4"t:) 117.6 ± 13.7'~ 
422 240 30 
248 137 26 
395 291 31 
452 226 59 
*p < 0.05 versus control group, tp < 0.05 versus rapid pacing group. ~:p < 
0.05 versus baseline. Data presented are mean value _+ SEM. Control + 
digoxin - sham controls with concomitant digoxin (0.25 mg/day); Rapid pac- 
ing = 28 days of right ventricular pacing at 210 beats/min; Rapid pacing + 
digoxin = rapid pacing with concomitant digoxin (0.25 rag/day). 
pared with the control group. In the pacing with digoxin 
treatment group, velocity of relengthening was 39% greater 
than in the rapid pacing only group. In the drug control group, 
there were no differences in myocyte length or indexes of 
myocyte contractile function compared with the group of 
untreated normal dogs. Thus, consistent with past reports 
(15,17,26,30), chronic rapid pacing resulted in reduced myo- 
cyte contractile performance. This study demonstrated that 
concomitant digoxin treatment during chronic rapid pacing 
improved myocyte contractile performance. 
In the next series of studies, the capacity of isolated 
myocytes to respond to an inotropic stimulus was examined 
after exposure to either the beta-adrenergic agonist isoproter- 
enol or increased extracellular calcium. The results from this 
series of experiments are shown in Table 3. Isolated myocyte 
contractile performance in the presence of isoproterenol r 
calcium was increased compared with baseline (no beta- 
adrenergic or calcium stimulation) values for all three groups. 
However, isolated myocyte function was significantly lower 
with isoproterenol rcalcium in the chronic rapid pacing group 
compared with the control group. Compared with the rapid 
pacing only group, concomitant digoxin treatment increased 
myocyte contractile function in the presence of beta- 
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Figure 1. Representative myocyte contraction profiles in control, 
chronic rapid pacing and rapid pacing with concomitant digoxin groups 
at baseline (left) and in the presence 25 nmol/liter of isoproterenol 
(right). Compared with the control value, myocyte l ngth was in- 
creased with both rapid pacing and rapid pacing with digoxin. Percent 
and velocity of shortening were diminished in the rapid pacing and the 
rapid pacing and digoxin groups compared with the control group. 
However, both percent and velocity of myoeyte shortening were 
greater with rapid pacing and concomitant digoxin compared with 
rapid pacing alone. In the presence ofisoproterenol, myocyte contrac- 
tion amplitude was increased in all groups compared with baseline 
values. However, both myocyte percent and velocity of shortening were 
diminished inthe rapid pacing and rapid pacing with digoxin groups 
compared with the control group. After beta-adrenergic re eptor 
stimulation, myocyte percent and velocity of shortening were greater 
with rapid pacing with concomitant digoxin than with rapid pacing 
alone. Indexes of myocyte contractile function at baseline and after 
beta-adrenergic e eptor stimulation are summarized in Table 3. 
adrenergic receptor stimulation. In contrast, myocyte contrac- 
tile function in the presence of increased extracellular calcium 
was not increased in the digoxin-treated group compared with 
the rapid pacing only group. In light of the differences in 
baseline myocyte function in the control, rapid pacing and 
rapid pacing with digoxin treatment groups, the magnitude of
the response to inotropic stimulation was examined as the 
absolute increase in velocity of shortening. This analysis was 
performed using paired values for shortening velocity in those 
myocytes which were exposed to either isoproterenol r in- 
creased extracellular calcium. The results of this analysis are 
summarized in Figure 2. Compared with the chronic rapid 
pacing group, concomitant digoxin treatment caused improved 
myocyte contractile performance with beta-adrenergie recep- 
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Figure 2. The absolute change from baseline for myocyte shortening 
velocity with 25 nmolfliter of isoproterenol (A) or 8 mmol/liter of 
extracellular calcium (B). Beta-adrenergic and calcium responsiveness 
was diminished in the chronic rapid pacing roup compared with the 
control group. With rapid pacing and digoxin, beta-adrenergic espon- 
siveness was normalized to the control value. In contrast, calcium 
responsiveness with rapid pacing and digoxin remained significantly 
diminished. *p< 0.05 versus control; +p < 0.05 versus rapid pacing. 
tor stimulation, but did not improve myocyte contractile 
function with exposure to increased extracellular calcium. 
Isolated myocyte electrophysiology: effect of rapid pacing 
and concomitant digoxin therapy. To determine the effect of 
rapid pacing with or without concomitant digoxin treatment on 
isolated myocyte lectrophysiologic measures, intracellular ac- 
tion potentials were recorded. Representative action potentials 
from each group are shown in Figure 3, and the data from this 
series of experiments are summarized in Table 4. In the 
chronic rapid pacing group compared with the control group, 
isolated myocyte rest membrane potential was more positive, 
maximal upstroke velocity decreased and action potential 
duration increased. With concomitant digoxin and rapid pac- 
ing, rest membrane potential normalized. Further, maximal 
upstroke velocity increased and action potential duration 
decreased compared with the pacing only group. Thus, chronic 
rapid pacing caused significant changes in isolated myocyte 
action potential characteristics. Concomitant digoxin treat- 
ment during the rapid pacing protocol normalized these im- 
portant characteristics of isolated myocyte lectrophysiology. 
In control dogs that underwent chronic digoxin treatment 
(drug control group), there was no change in isolated myocyte 
action potential characteristics. In the drug control group 
compared with the group of untreated normal dogs, there was 
no change in rest membrane potential or any other myocyte 
action potential variable. Thus, chronic digoxin administration 
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Figure 3. Representative isolated myocyte action potentials in the 
control, chronic rapid pacing and rapid pacing with concomitant 
digoxin groups. In the rapid pacing roup, rest membrane potential 
was more positive, maximal upstroke velocity was decreased and action 
potential duration was prolonged compared with the control group. 
With rapid pacing and digoxin, action potential variables were normal- 
ized. Indexes of action potential data for the three groups are 
summarized in Table 4. 
in the presence of normal myocardium had no effect on 
isolated myocyte lectrophysiologic measures. 
Discuss ion  
Congestive heart failure is a significant cause of morbidity 
and mortality, and the prevalence is increasing (18). Thus, 
attempts to discern potential mechanisms of current herapeu- 
tic interventions in the setting of heart failure remain a major 
focus of cardiovascular research. The cardiac glycoside prepa- 
ration digoxin is a common therapeutic agent used in patients 
with heart failure. However, the mechanism of action for 
chronic digoxin therapy in the setting of LV failure remains 
unclear (11). Accordingly, the present study addressed these 
issues in a model of tachycardia-induced LV dysfunction with 
and without concomitant digoxin therapy. There were several 
important and unique findings of this study. First, concomitant 
digoxin with chronic rapid pacing improved LV and myocyte 
function, compared with chronic pacing alone. Second, con- 
comitant digoxin with chronic rapid pacing normalized myo- 
cyte beta-adrenergic responsiveness. Third, concomitant 
digoxin treatment with chronic rapid pacing normalized abnor- 
malities in myocyte action potential characteristics. Thus, this 
study provides unique evidence to suggest hat the cellular 
basis for improved LV pump function with digoxin treatment 
during the progression of LV failure has a direct and beneficial 
effect on myocyte contractile function and electrophysiologic 
measures. 
Although there is an historic precedent for the use of 
digitalis glycoside agents in the setting of congestive heart 
failure (1,2), only recently have clinical trials demonstrated the 
benefits of this therapeutic modality. Specifically, large multi- 
center trials have demonstrated that digoxin administration 
improves symptoms and echocardiographic indexes of LV 
function in patients with congestive heart failure (4,5,7,8). 
Other clinical trials have demonstrated that for patients with 
LV dysfunction digoxin is the only available positive inotropic 
agent hat reduces ymptoms without a demonstrable increase 
in mortality (6,31). Therefore, there is reasonable clinical 
evidence to support he use of digoxin in patients with LV 
dysfunction, but the mechanisms underlying the beneficial 
effects remain unclear. To our knowledge, the present study is 
the first to examine the direct effects of digoxin therapy on LV 
and myocyte function with the development of chronic LV 
failure. The findings of the present study provide direct 
evidence that a contributory mechanism for improved LV 
Table 4. Myocyte Action Potential Characteristics With Chronic Rapid Pacing: Effects of Long-Term 
Digoxin Treatment 
Control + Rapid Pacing Rapid Pacing + 
Control Group Digoxin Group Group Digoxin Group 
Rest membrane potential (mV) -80,6 ± 0.8 -79.8 _+ 1.3 -74.0 ± 1.1" -77.3 + 1,2 
Maximal upstroke velocity (V/s) 163 _+ 9 156 _+ 8 135 ± 6* 155 -+ 12t 
Action potential amplitude (mV) 107 _+ 2 113 ± 2 106 _+ 2 109 _+ 2t 
APDso (ms) 162 _+ 6 169 + 10 154 = 8 160 ± 14 
APDg~  (ms) 216 _+ 6 221 -+ 10 247 _+ 10" 219 + 12t 
No. of cells 21 20 21 14 
*p < 0.05 versus control group, tP < 0.05 versus rapid pacing group. Data presented are mean value + SEM. 
APD~ 0 = action potential duration at 50% repolarization; APDgo = action potential duration at 90% repolarization; 
Control + Digoxin = sham control group with concomitant digoxin (0.25 mg/day); Rapid Pacing - 28 days of right 
ventricular pacing at 210 beats/rain; Rapid Pacing + DigoxJn = rapid pacing with concomitant digoxin (0.25 mg/day). 
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pump function with chronic digoxin therapy has direct benefi- 
cial effects on myocyte contractile processes. 
Left ventricular geometry and function. In the present 
study, concomitant digoxin treatment with chronic rapid pac- 
ing caused a slight but significant increase in LV ejection 
fraction, but did not prevent the progressive LV dilation, which 
invariably occurs with chronic rapid pacing (15,17,20,24,26,30). 
The increased LV ejection fraction observed in the present 
study with chronic digoxin therapy is consistent with clinical 
reports (6,7,32). In addition, Sabbah et al. (21) recently 
reported that digoxin therapy in dogs with progressive LV 
dysfunction due to microembolization improved LV ejection 
fraction, but that progressive LV dilation was not prevented. In
the present study, digoxin therapy with chronic rapid pacing 
improved LV ejection fraction but did not prevent LV dilation. 
Although not statistically significant, both LV peak and end- 
systolic wall stresses were lower in the rapid pacing group 
treated with digoxin compared with the rapid pacing only 
group. Thus, changes in LV afterload may have contributed to
the increased LV ejection fraction in the rapid pacing group 
treated with digoxin. However, a more likely contributory 
factor toward the improvement i  LV ejection fraction was the 
improvement in myocyte contractile function in the rapid 
pacing roup treated with digoxin. 
Digoxin treatment exerts both direct and indirect effects on 
cardiac electrophysiologic measures, and some of these effects 
are reflected in ECG changes (19). In the present study, ECG 
changes that occurred with the development of rapid pacing- 
induced LV pump failure included an increased heart rate, 
prolonged QRS duration and prolonged QTc interval. Con- 
comitant digoxin therapy with chronic rapid pacing reduced 
the ambient rest heart rate, prolonged the PR interval and 
shortened the QTc interval. Thus, concomitant digoxin treat- 
ment caused specific hanges in electrocardiography t at are 
consistent with clinical observations (19). Importantly, these 
measurements were obtained at steady state ambient heart 
rate at least 30 min after pacemaker deactivation. However, in 
the present study, the induction of LV pump failure was 
performed using a constant, pacing-induced, ventricular rate. 
This chronic pacing rate probably removed any influence that 
chronic digoxin therapy would have on myocardial ctivation 
processes. The use of this model of chronic LV dysfunction 
effectively removed the potential confounding influence of 
heart rate modulation by chronic digoxin therapy. Therefore, 
the beneficial effects of chronic digoxin therapy on LV and 
myocyte function in this model of LV dysfunction were not 
related to effects of digoxin on heart rate control or myocardial 
activation processes. 
Isolated myocyte geometry and contractile function. Con- 
sistent with past reports from our laboratory (15,17,26), iso- 
lated myocyte length was increased and myocyte cross- 
sectional area was decreased with rapid pacing-induced LV
failure. Concomitant digoxin therapy with chronic rapid pacing 
improved but did not normalize isolated myocyte l ngth and 
myocyte cross-sectional area. Thus, a structural basis for the 
persistent LV dilation observed with chronic rapid pacing and 
concomitant digoxin therapy was continued abnormalities in 
myocyte geometry. Past studies have provided evidence that 
potential mechanisms for the LV and myocyte r modeling with 
chronic rapid pacing are myocyte remodeling, realignment of
myocytes within the LV free wall and an absolute reduction in 
the number of myocytes (33,34). For example, in a recent 
report by Kajstura et al. (34), a significant loss in myocytes 
within the LV free wall was reported to occur after chronic 
ventricular pacing tachycardia n dogs. Thus, an important 
contributory event toward the changes in LV myocardial 
remodeling with pacing-induced failure may be myocyte drop- 
out, or apoptosis. Although the specific ellular mechanisms 
responsible for the LV remodeling that occurs with chronic 
rapid pacing remain to be established, the results from the 
present study demonstrated that digoxin therapy did not 
prevent he changes in LV and myocyte geometry, which 
invariably occur in this model of LV failure. 
Myocyte beta.adrenergic and calcium response. To exam- 
ine the capacity of myocytes to respond to an inotropic 
stimulus, myocyte contractile function was examined after 
exposure to the beta-adrenergic agonist isoproterenol. Consis- 
tent with past reports, chronic rapid pacing caused reduced 
myocyte beta-adrenergic responsiveness (15,17). Concomitant 
digoxin treatment with rapid pacing normalized myocyte beta- 
adrenergic responsiveness. It has been proposed that, similar 
to clinical findings (35), possible mechanisms for diminished 
beta-adrenergic responsiveness with rapid pacing-induced LV
pump failure include levated circulating catecholamines with 
subsequent beta-receptor downregulation, alterations in the 
guanine nucleotide-binding re ulatory complex and abnormal- 
ities in cyclic AMP production (13,14,17). In the present study, 
chronic rapid pacing increased plasma norepinephrine levels. 
Concomitant digoxin with chronic rapid pacing attenuated the 
increase in circulating norepinephrine levels. Past studies have 
shown that digoxin directly attenuates increased sympathetic 
activity present in clinical heart failure (36). Further, it has 
been demonstrated that digoxin can directly decrease the 
sympathetic efferent activity that occurs in pacing-induced LV 
pump dysfunction through a direct increase in baroreceptor 
sensitivity (37). Therefore, the reduced levels of plasma nor- 
epinephrine which were observed with concomitant digoxin 
and chronic rapid pacing are probably due to modulation of 
sympathetic efferent activity. More importantly, a potential 
contributory mechanism for the improved myocyte beta- 
adrenergic response with concomitant digoxin therapy in the 
setting of rapid pacing-induced LV dysfunction is a reduction 
in circulating catecholamines, and subsequent improved beta- 
adrenergic transduction. However, concomitant digoxin ther- 
apy with chronic rapid pacing did not return myocyte beta- 
adrenergic responsiveness to control levels. Our laboratory 
and those of others have demonstrated that the abnormalities 
in beta-adrenergic receptor transduction and responsiveness 
with pacing-induced LV failure were associated with alter- 
ations in the guanine nucleotide-binding regulatory protein 
complex (G-protein complex) (13,14,17,30). Furthermore, the 
development of cardiomyopathic disease has been demon- 
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strated to cause alterations inbeta-adrenergic re eptor subtype 
expression (35). Potential mechanisms for the continued re- 
duction in myocyte beta-adrenergic responsiveness with con- 
comitant digoxin treatment and rapid pacing include abnor- 
malities in subtype xpression or in the G-protein complex. 
Future studies that more carefully examine specific hanges in 
beta-adrenergic receptor density and transduction with con- 
comitant digoxin treatment and the progression of pacing LV 
failure would be appropriate. 
The cardiac glycosides act by binding to and blocking the 
action of the membrane bound Na+,K+-ATPase. This enzyme 
hydrolyzes ATP in order to transport sodium into the extra- 
cellular space and to transport potassium into the cell. The 
Na+,K+-ATPase is therefore a major contributor to cellular 
ionic homeostasis and maintenance of the rest membrane 
potential. The inotropic action of cardiac glycosides i  likely a 
result of Na+,K+-ATPase inhibition, which results in a slight 
increase in intracellular sodium concentration ([Na+]i). This 
increased [Na+]i is then available as a substrate for the 
sarcolemmal Na+/Ca 2+ exchange system, resulting in in- 
creased [Ca2+]i and increased contractility (38,39). In the 
present study, chronic rapid pacing caused iminished myocyte 
contractile responsiveness to increased extracellular calcium. 
This was not an unexpected finding, because abnormalities in 
calcium homeostasis and myofilament sensitivity to calcium 
have been reported with pacing-induced heart failure (15,40- 
42). Thus, the blunted response to increased extracellular 
calcium with rapid pacing is probably an exacerbation of 
preexisting abnormalities in intracellular calcium regulation. In 
the present study, concomitant digoxin treatment with chronic 
rapid pacing failed to normalize myocyte responsiveness to 
increased extracellular calcium. This observation suggests that 
persistent defects in myocyte calcium homeostasis occurred 
with concomitant digoxin therapy in this model of chronic LV 
pump failure. An important intracellular mechanism ofaction 
with beta-receptor activation is increased calcium availability. 
Thus, the uncorrected defect in myocyte calcium response with 
rapid pacing and digoxin treatment is also a likely contributory 
factor toward persistently diminished myocyte beta-adrenergic 
response. In the present study, chronic digoxin treatment and 
rapid pacing improved myocyte beta-adrenergic response to a 
greater degree than the calcium response. This observation is 
likely related to the mechanism by which beta-adrenergic 
stimulation ormally increases myocyte inotropic state, specif- 
ically cyclic AMP-dependent phosphorylation f regulatory 
proteins (38). Therefore, the difference inbeta-adrenergic and 
calcium responsiveness with digoxin and chronic rapid pacing 
is likely due to improvements in phosphorylation capacity 
rather than improvements in calcium homeostatic processes. 
Isolated myoeyte lectrophysiology. Ionic currents across 
the sarcolemma during the myocyte action potential are a 
determinant of myocyte xcitation-contraction processes (38). 
Previous studies have demonstrated specific alterations in 
myocyte action potential characteristics with chronic rapid 
pacing in pigs, and these changes were directly associated with 
alterations inmyocyte contractile function (28). In the present 
study, chronic rapid pacing caused specific hanges in isolated 
myocyte action potential characteristics. These changes in- 
cluded more positive rest membrane potential, decreased 
maximal upstroke velocity and increased action potential du- 
ration. Chronic digoxin therapy with rapid pacing normalized 
these action potential characteristics. To our knowledge, the 
present study is the first to examine the specific changes in 
ventricular myocyte action potential characteristics with 
chronic digoxin therapy in the setting of pacing-induced LV
pump failure. It is difficult o directly relate the action potential 
findings to the ECG data, which were obtained in vivo. 
Nevertheless, the improvements in action potential character- 
istics which were observed in digoxin therapy with chronic 
rapid pacing probably contributed to improved myocyte con- 
tractile function. In the present study, isolated myocyte con- 
tractile function and electrophysiologic characteristics were 
measured 4 to 8 h after removal of the heart and more than 
36 h after the last digoxin dose. Thus, the myocyte contractile 
function and action potential data obtained in the present 
study reflect the chronic effects of digoxin treatment with 
chronic rapid pacing rather than the direct effect of digoxin on 
action potential characteristics. Moreover, the time to 50% 
dissociation of ouabain bound to sarcolemmal vesicles has 
been previously reported by this laboratory to be approxi- 
mately 77 min (26). Therefore, it is unlikely that the myocyte 
contractile function and action potential data were affected by 
digoxin bound to the sarcolemma of the isolated myocytes. 
In the clinical setting, digoxin is routinely administered 
simultaneously with chronic diuretic therapy (6,7,32). In the 
present study, all experimental nimals that underwent rapid 
pacing received daily furosemide treatment. With chronic 
rapid pacing alone, LV function and isolated myocyte contrac- 
tile function were identical to values previously published from 
this laboratory in animals with rapid pacing-induced LV pump 
dysfunction (20,30). Thus, chronic diuretic therapy did not 
influence the changes in LV and myocyte geometry and 
function that occur with the development of rapid pacing- 
induced LV pump dysfunction. To examine the effect of 
digoxin treatment on LV and myocyte function in normal 
myocardium, a subset of control dogs was treated with digoxin. 
With digoxin treatment in normal dogs, LV dimension and 
ejection fraction and isolated myocyte l ngth shortening veloc- 
ity were unchanged from control values. Thus, chronic digoxin 
treatment in normal myocardium had no effect on LV and 
myocyte geometry and function. 
Limitations. The present study demonstrated that digoxin 
has direct beneficial effects on LV and myocyte geometry, 
function and electrophysiologic measures but the fundamental 
mechanisms responsible for these improvements were not 
addressed. Specifically, important sarcolemmal enzyme sys- 
tems such as Na+,K+-ATPase and the Na+-Ca 2+ exchanger 
were not examined. Furthermore, it is well recognized that 
chronic therapeutic modalities that modulate receptor activi- 
ties are associated with alterations in receptor number and 
transduction. Our laboratory has previously demonstrated that 
rapid pacing-induced LV pump dysfunction causes reduced 
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glycoside receptor density and Na+,K+-ATPase activity (26). 
A recent report (43) did not detect a change in human LV 
Na+,K+-ATPase concentration with chronic digitalization, but 
the effects of chronic digoxin therapy with respect o Na+,K +- 
AYPase density and function in this model of LV pump 
dysfunction remain to be established. Based on the findings of 
the present study, future studies that quantitate glycoside 
receptor binding and Na+,K+-ATPase hydrolytic activity with 
chronic digoxin therapy in this model of chronic LV dysfunc- 
tion may be appropriate. In the clinical setting, digoxin therapy 
is initiated after the development ofsigns and symptoms of LV 
dysfunction. It remains unclear from the present study whether 
digoxin therapy prevents the continued deterioration in LV 
and myocyte function in the setting of preexisting LV dysfunc- 
tion. Thus, the time-dependent effects of digoxin therapy in 
this model of LV dysfunction remain to be established. In light 
of the fact that consistent ime-dependent changes in LV 
function occur with chronic rapid pacing (13,19), this model of 
LV dysfunction would be well suited to study the time- 
dependent effects of digoxin therapy. 
Conclusions. Although digoxin historically has been used 
in the treatment of heart failure, the fundamental mechanisms 
responsible for the clinical benefit of this therapeutic modality 
remain unclear. Accordingly, the present study examined the 
effects of chronic digoxin therapy on both ventricular and 
isolated myocyte function in an experimental model of chronic 
LV dysfunction. Digoxin treatment improved LV pump func- 
tion, enhanced isolated myocyte contractile performance and 
beta-adrenergic responsiveness and normalized myocyte action 
potential characteristics. This study provides unique evidence 
that the fundamental basis for improved LV pump function 
with digoxin treatment in chronic heart failure has a direct 
beneficial effect on myocyte contractile function and electro- 
physiologic measures. 
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